These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 25691567)

  • 41. Clade C HIV-1 Envelope Vaccination Regimens Differ in Their Ability To Elicit Antibodies with Moderate Neutralization Breadth against Genetically Diverse Tier 2 HIV-1 Envelope Variants.
    Burton S; Spicer LM; Charles TP; Gangadhara S; Reddy PBJ; Styles TM; Velu V; Kasturi SP; Legere T; Hunter E; Pulendran B; Amara R; Hraber P; Derdeyn CA
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30651354
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site.
    Wibmer CK; Gorman J; Anthony CS; Mkhize NN; Druz A; York T; Schmidt SD; Labuschagne P; Louder MK; Bailer RT; Abdool Karim SS; Mascola JR; Williamson C; Moore PL; Kwong PD; Morris L
    J Virol; 2016 Nov; 90(22):10220-10235. PubMed ID: 27581986
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.
    Townsley S; Li Y; Kozyrev Y; Cleveland B; Hu SL
    J Virol; 2016 Jan; 90(2):829-41. PubMed ID: 26512079
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunogenic Display of Purified Chemically Cross-Linked HIV-1 Spikes.
    Leaman DP; Lee JH; Ward AB; Zwick MB
    J Virol; 2015 Jul; 89(13):6725-45. PubMed ID: 25878116
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant.
    Wen Y; Trinh HV; Linton CE; Tani C; Norais N; Martinez-Guzman D; Ramesh P; Sun Y; Situ F; Karaca-Griffin S; Hamlin C; Onkar S; Tian S; Hilt S; Malyala P; Lodaya R; Li N; Otten G; Palladino G; Friedrich K; Aggarwal Y; LaBranche C; Duffy R; Shen X; Tomaras GD; Montefiori DC; Fulp W; Gottardo R; Burke B; Ulmer JB; Zolla-Pazner S; Liao HX; Haynes BF; Michael NL; Kim JH; Rao M; O'Connell RJ; Carfi A; Barnett SW
    PLoS One; 2018; 13(4):e0194266. PubMed ID: 29698406
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies.
    Moore JP; McCutchan FE; Poon SW; Mascola J; Liu J; Cao Y; Ho DD
    J Virol; 1994 Dec; 68(12):8350-64. PubMed ID: 7525988
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Epitope-focused immunogens against the CD4-binding site of HIV-1 envelope protein induce neutralizing antibodies against auto- and heterologous viruses.
    Wang H; Chen X; Wang D; Yao C; Wang Q; Xie J; Shi X; Xiang Y; Liu W; Zhang L
    J Biol Chem; 2018 Jan; 293(3):830-846. PubMed ID: 29187598
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Membrane Env Liposomes Facilitate Immunization with Multivalent Full-Length HIV Spikes.
    Leaman DP; Stano A; Chen Y; Zhang L; Zwick MB
    J Virol; 2021 Jun; 95(13):e0000521. PubMed ID: 33883221
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins.
    Grundner C; Li Y; Louder M; Mascola J; Yang X; Sodroski J; Wyatt R
    Virology; 2005 Jan; 331(1):33-46. PubMed ID: 15582651
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins.
    Schiffner T; Pallesen J; Russell RA; Dodd J; de Val N; LaBranche CC; Montefiori D; Tomaras GD; Shen X; Harris SL; Moghaddam AE; Kalyuzhniy O; Sanders RW; McCoy LE; Moore JP; Ward AB; Sattentau QJ
    PLoS Pathog; 2018 May; 14(5):e1006986. PubMed ID: 29746590
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs.
    Nkolola JP; Peng H; Settembre EC; Freeman M; Grandpre LE; Devoy C; Lynch DM; La Porte A; Simmons NL; Bradley R; Montefiori DC; Seaman MS; Chen B; Barouch DH
    J Virol; 2010 Apr; 84(7):3270-9. PubMed ID: 20053749
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Selected HIV-1 Env trimeric formulations act as potent immunogens in a rabbit vaccination model.
    Heyndrickx L; Stewart-Jones G; Jansson M; Schuitemaker H; Bowles E; Buonaguro L; Grevstad B; Vinner L; Vereecken K; Parker J; Ramaswamy M; Biswas P; Vanham G; Scarlatti G; Fomsgaard A;
    PLoS One; 2013; 8(9):e74552. PubMed ID: 24023951
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Envelope-Based Fusion Antigen GP120C14K Forming Hexamer-Like Structures Triggers T Cell and Neutralizing Antibody Responses Against HIV-1.
    Raman SC; Mejías-Pérez E; Gomez CE; García-Arriaza J; Perdiguero B; Vijayan A; Pérez-Ruiz M; Cuervo A; Santiago C; Sorzano COS; Sánchez-Corzo C; Moog C; Burger JA; Schorcht A; Sanders RW; Carrascosa JL; Esteban M
    Front Immunol; 2019; 10():2793. PubMed ID: 31867001
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
    Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses.
    Mouquet H; Klein F; Scheid JF; Warncke M; Pietzsch J; Oliveira TY; Velinzon K; Seaman MS; Nussenzweig MC
    PLoS One; 2011; 6(9):e24078. PubMed ID: 21931643
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Variations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade C env clones obtained at different time points from antiretroviral naïve Indian patients with recent infection.
    Ringe R; Thakar M; Bhattacharya J
    Retrovirology; 2010 Sep; 7():76. PubMed ID: 20860805
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration.
    D'Souza MP; Geyer SJ; Hanson CV; Hendry RM; Milman G
    AIDS; 1994 Feb; 8(2):169-81. PubMed ID: 7519019
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antigenic properties of the HIV envelope on virions in solution.
    Ray K; Mengistu M; Yu L; Lewis GK; Lakowicz JR; DeVico AL
    J Virol; 2014 Feb; 88(3):1795-808. PubMed ID: 24284318
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site.
    Feng Y; McKee K; Tran K; O'Dell S; Schmidt SD; Phogat A; Forsell MN; Karlsson Hedestam GB; Mascola JR; Wyatt RT
    J Biol Chem; 2012 Feb; 287(8):5673-86. PubMed ID: 22167180
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.
    Townsley S; Mohamed Z; Guo W; McKenna J; Cleveland B; LaBranche C; Beaumont D; Shen X; Yates NL; Pinter A; Tomaras GD; Ferrari G; Montefiori DC; Hu SL
    J Virol; 2016 Oct; 90(19):8644-60. PubMed ID: 27440894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.